Rosenberg JE, O'Donnell PH, Petrylak DP, Flaig TW, Hoimes CJ, Gupta S, Mar N, Friedlander TW, Tagawa ST, Bilen MA, Brown JR, McKay RR, Merchan JR, Srinivas S, Gorla S, Moreno BH, Davis G, Wirtz HS, Zhu Y, Milowsky MI. EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma. ESMO Open. 2026 Jun; 11(6):107700.

Khaitan A, Lindsey JC, Capparelli EV, Tierney C, Coletti A, Perlowski C, Yin DE, Smith MEB, Spiegel HML, Majji S, Moye J, Gama L, Koup RA, Lin BC, McDermott AB, Purdue L, Krotje C, Harding PA, Cotton MF, Costello D, Petropoulos CJ, Reeves JD, Mallewa M, Chihana R, Kamthunzi P, Mbengeranwa TG, Masheto G, Santos Cruz ML, Pilotto JH, Ponatshego PL, Persaud D, McFarland EJ. VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declines. Sci Transl Med. 2026 May 06; 18(848):eadr4509.

Colasanti JA, Aldredge A, Niles-Carnes LV, Ochieng E, Pareek P, Robinson V, Anderson E, Castaneda M, Spralling H, Smith BL, Sumitani J, Paul Leue E, Moran CA, Lora M, Armstrong WS, Collins LF. Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South. Clin Infect Dis. 2026 Apr 30; 82(4):564-574.

Panicker AJ, Hinman SS, Perreau J, Aslanpour A, Williams RL, Steinke S, Quinn E, Hernandez AL, Yandamuri SS, Irani SR, Longbrake EE, O'Connor KC. Generation of Monoclonal Autoantibodies From Myelin Oligodendrocyte Glycoprotein-Specific Human B Cells Using an Optofluidic-Based Platform. Neurol Neuroimmunol Neuroinflamm. 2026 May; 13(3):e200577.

Mollica V, Massari F, Fujita K, Giannatempo P, Grande E, Büttner T, Bourlon MT, Taha T, Fukuokaya W, Myint ZW, Pichler R, Binz K, Molina-Cerrillo J, Kopecky J, de Liaño AG, Kucharz J, Fiala O, Matrana MR, Kopp RM, Di Civita MA, Zgura A, Ansari J, Kihnel R, De Felice F, Angel M, Monteiro FSM, Soares A, Urun Y, Buti S, Santini D, Santoni M. Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV). Cancer Immunol Immunother. 2026 Mar 24; 75(4).

Dai Y, Brouillard J, Jaycox JR, Yeon SM, Huck JD, Yandamuri SS, Zhong Z, O'Connor KC, Burnina I, Henkel C, LeMay AK, Lilov A, McGurk E, Morrill M, Parker L, Sackett T, Sandberg C, Sivasubramanian A, Geoghegan JC, Ring AM. Off-target reactivity in clinical monoclonal antibodies. Structure. 2026 May 07; 34(5):747-757.e5.

Lerman BJ, King M, Mody R, Onyeama SJ, Marachelian A, Cash T, Federico SM, Granger M, Desai AV, Shusterman S, Foster JH, Sokol E, Greer C, Streby K, Meany HJ, Vo KT, Macy ME, Bagatell R. Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.

Zoref-Lorenz A, Allen CE, Behrens EM, Chandrakasan S, Chien M, Hermiston ML, Hinson AP, Intzes S, Isakoff MS, Leiding JW, Oladapo A, Panigrahi A, Patel SA, Pednekar P, Ray AK, Rothman JA, Saldaña BD, Walkovich KJ, Weinstein J, Yee JD, Jordan MB, Weinstein J, Hinson AP, Allen CE, Eckstein OS, Gulati N, Chandrakasan S, Haines H, Nakano TA, Patel SA, Behrens EM, Intzes S, Hays A, Saldaña BD, Jordan MB, Zoref-Lorenz A, Hanna R, Isakoff M, Ray AK, Rothman JA, Tandra A, Cooper R, Leiding JW, Chien M, Sarangi S, Gidvani-Diaz VK, Satwani P, Carter J, Henry M, Gloude N, Bhatt S, Bhatla D, Draper L, Panigrahi A, Hermiston ML, Modica R, Riskalla M, Baker A, Ward B. Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: the REAL-HLH study. Blood Adv. 2026 Mar 10; 10(5):1564-1575.

Tang AH, Soler NM, Karlic KI, Corcilius L, Clarke-Shepperson CE, Lehmann C, Debowski AW, Dale AL, Zavan L, Cielesh M, Adewale AP, Moulton KD, Li L, Guan C, McCrory C, Kaparakis-Liaskos M, Howden BP, Sherry NL, Wei R, Li X, Hall RM, Kenyon JJ, Wakim LM, Short FL, Dube DH, Cordwell SJ, Larance M, Stubbs KA, Carter GP, Scott NE, Goddard-Borger ED, Payne RJ. Uncovering bacterial pseudaminylation with pan-specific antibody tools. Nat Chem Biol. 2026 Apr; 22(4):622-633.

Stein Gold L, Gottlieb AB, Armstrong AW, Alkousakis T, Bissonnette R, Langley RG, Krueger J, Papp K, Choi O, Rowland K, Chan D, Jeyarajah J, Park-Wyllie L, Gao LL, Gordon KB, Merola JF, Lebwohl MG, Strober B. SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement. Br J Dermatol. 2026 01 06; 194(1):25-36.